Premium
IMMUNOLOGICAL RECONSTITUTION IN A PATIENT WITH SEVERE COMBINED IMMUNE DEFICIENCY USING NON‐SIBLING BONE MARROW DEPLETED OF T CELLS WITH HuLy‐m1
Author(s) -
ROBERTON D. M.,
GEORGIOU G. M.,
TIEDEMANN K.,
HOSKING C. S.,
FERRANTE A.,
TOOGOOD I.,
McKENZlE I. F. C.
Publication year - 1986
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1986.tb01193.x
Subject(s) - medicine , immunology , bone marrow , immune system , percoll , lymphocyte , methotrexate , in vitro , biology , biochemistry
An infant with severe immune deficiency received bone marrow from an HLA‐A, ‐B, ‐DR matched, mixed leucocyte reaction non‐reactive first cousin. The donor marrow was fractionated on a discontinuous Percoll gradient and before infusion was treated with the anti‐human T lymphocyte antibody, HuLy‐m1, and rabbit serum as a source of complement. Methotrexate was given during the following two weeks. A rise in the peripheral blood lymphocyte count, indicating engraftment, occurred six weeks after transplantation. There was no clinical evidence of graft versus host disease (GVHD). Engraftment has been sustained for one year and the patient is in normal health and has normal in vitro immunological function. In vitro treatment of human marrow with HuL‐m1 allows stable engraftment and may be useful in attempting to diminish or prevent GVHD.